Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cell-permeable CFB inhibitor
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
01
Overview
The cell-permeable CFB inhibitor (also known as cpFBinh or CFBi) is a small molecule inhibitor of complement factor B (CFB) developed by GSK. It is designed to rapidly diffuse across cell membranes to target and inhibit intracellular CFB, a key component of the alternative pathway C3 convertase. By blocking intracellular CFB, the inhibitor prevents the cell-intrinsic activation of C3 and subsequent downstream complement signaling. This tool compound has been widely used in preclinical research to investigate the role of the intracellular complement system (the complosome) in various pathological processes, including SARS-CoV-2-induced lung epithelial cell inflammation, post-injury kidney fibrosis, and macrophage-mediated inflammatory responses.
- Other names
- CFBi-Fcell-permeable complement factor B inhibitorcell-permeable factor B inhibitorintracellular CFB inhibitorintracellular complement factor B inhibitor
02
Targets
CFB (Complement Factor B)
Beyond the preview
Go deeper on cell-permeable CFB inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cell-permeable CFB inhibitor.